eFFECTOR Therapeutics, Inc. (EFTR)
OTCMKTS · Delayed Price · Currency is USD
0.0008
0.00 (0.00%)
At close: Sep 2, 2026
eFFECTOR Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 15.51 | 14.88 | 8.71 | 49.7 | 15.22 | 3.43 |
Short-Term Investments | 9.88 | 3.5 | 17.6 | - | - | - |
Cash & Short-Term Investments | 25.38 | 18.37 | 26.31 | 49.7 | 15.22 | 3.43 |
Cash Growth | 33.55% | -30.18% | -47.06% | 226.64% | 344.00% | - |
Other Receivables | 0.02 | 0.05 | 0.03 | - | - | - |
Receivables | 0.02 | 0.05 | 0.03 | - | - | - |
Prepaid Expenses | 0.85 | 1.42 | 1.68 | 3.19 | 1.36 | 0.85 |
Total Current Assets | 26.25 | 19.84 | 28.01 | 52.9 | 16.58 | 4.27 |
Property, Plant & Equipment | 0.42 | 0.19 | 0.35 | 0.26 | 0.13 | 0.82 |
Other Long-Term Assets | 0.47 | 0.51 | 0.71 | 0.9 | - | - |
Total Assets | 27.13 | 20.54 | 29.08 | 54.06 | 16.7 | 5.1 |
Liabilities
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Accounts Payable | 1.71 | 2.33 | 1.49 | 0.52 | 0.35 | 0.6 |
Accrued Expenses | 3.79 | 2.92 | 3.37 | 3.07 | 1.63 | 2.65 |
Short-Term Debt | - | - | - | - | - | 14.73 |
Current Portion of Long-Term Debt | 20.02 | 20.49 | 20.16 | - | 5.91 | - |
Current Portion of Leases | 0.05 | 0.06 | 0.06 | 0.04 | 0.11 | 0.51 |
Current Income Taxes Payable | - | - | - | 0.35 | 0.35 | - |
Other Current Liabilities | - | - | - | - | 0.43 | 0.44 |
Total Current Liabilities | 25.57 | 25.8 | 25.08 | 3.98 | 8.78 | 18.93 |
Long-Term Debt | - | - | - | 19.86 | 6.95 | - |
Long-Term Leases | 0.18 | - | 0.06 | 0.13 | - | - |
Other Long-Term Liabilities | 0.56 | 0.54 | 0.05 | 12.81 | - | - |
Total Liabilities | 26.3 | 26.34 | 25.18 | 36.77 | 15.73 | 18.93 |
Shareholders' Equity
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Common Stock | - | - | - | 0 | - | - |
Additional Paid-In Capital | 189.04 | 173.58 | 147.48 | 138.18 | 4.45 | 3.85 |
Retained Earnings | -188.21 | -179.38 | -143.57 | -120.9 | -136.7 | -150.91 |
Comprehensive Income & Other | - | - | -0.02 | - | - | - |
Total Common Equity | 0.83 | -5.8 | 3.9 | 17.28 | -132.25 | -147.06 |
Shareholders' Equity | 0.83 | -5.8 | 3.9 | 17.28 | 0.98 | -13.84 |
Total Liabilities & Equity | 27.13 | 20.54 | 29.08 | 54.06 | 16.7 | 5.1 |
Additional Metrics
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Total Debt | 20.25 | 20.55 | 20.28 | 20.03 | 12.96 | 15.25 |
Net Cash (Debt) | 5.14 | -2.18 | 6.03 | 29.67 | 2.26 | -11.82 |
Net Cash Growth | - | - | -79.68% | 1215.83% | - | - |
Net Cash Per Share | 1.84 | -0.99 | 3.66 | 20.60 | 21.23 | -247.06 |
Filing Date Shares Outstanding | 4.7 | 3.69 | 1.7 | 1.66 | 1.63 | 0.05 |
Total Common Shares Outstanding | 3.9 | 2.98 | 1.67 | 1.62 | 1.45 | 0.05 |
Working Capital | 0.68 | -5.96 | 2.94 | 48.92 | 7.8 | -14.66 |
Book Value Per Share | 0.21 | -1.94 | 2.34 | 10.70 | -91.51 | -3074.38 |
Tangible Book Value | 0.83 | -5.8 | 3.9 | 17.28 | -132.25 | -147.06 |
Tangible Book Value Per Share | 0.21 | -1.94 | 2.34 | 10.70 | -91.51 | -3074.38 |
Machinery | 0.34 | 0.26 | 0.24 | 0.22 | 0.23 | 2.09 |
Construction In Progress | 0.01 | 0.01 | 0.03 | 0.07 | - | - |
Leasehold Improvements | 0.19 | 0.19 | 0.19 | - | - | 1.07 |